Related references
Note: Only part of the references are listed.Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer
Charu Aggarwal et al.
JAMA ONCOLOGY (2019)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
N. Guibert et al.
ANNALS OF ONCOLOGY (2018)
False-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Zhijie Wang et al.
LANCET RESPIRATORY MEDICINE (2018)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Viktor A. Adalsteinsson et al.
NATURE COMMUNICATIONS (2017)
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer
Filip Janku et al.
CLINICAL CANCER RESEARCH (2017)
Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast lung and prostate cancer.
Pedram Razavi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers
B. T. Li et al.
ANNALS OF ONCOLOGY (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer
Geoffrey R. Oxnard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma The Lung Cancer Mutation Consortium Experience
Lynette M. Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2014)
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Alain R. Thierry et al.
NATURE MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
Steven M. Teutsch et al.
GENETICS IN MEDICINE (2009)
Share Paper
